WO2005004988A3 - Compositions and methods relating to novel compounds and targets thereof - Google Patents

Compositions and methods relating to novel compounds and targets thereof Download PDF

Info

Publication number
WO2005004988A3
WO2005004988A3 PCT/US2004/013455 US2004013455W WO2005004988A3 WO 2005004988 A3 WO2005004988 A3 WO 2005004988A3 US 2004013455 W US2004013455 W US 2004013455W WO 2005004988 A3 WO2005004988 A3 WO 2005004988A3
Authority
WO
WIPO (PCT)
Prior art keywords
targets
compositions
novel compounds
methods relating
methods
Prior art date
Application number
PCT/US2004/013455
Other languages
French (fr)
Other versions
WO2005004988A2 (en
Inventor
Gary D Glick
Anthony W Opipari
Original Assignee
Univ Michigan
Gary D Glick
Anthony W Opipari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/427,211 external-priority patent/US7572788B2/en
Priority claimed from US10/634,114 external-priority patent/US20040176358A1/en
Priority claimed from US10/795,535 external-priority patent/US7276348B2/en
Application filed by Univ Michigan, Gary D Glick, Anthony W Opipari filed Critical Univ Michigan
Priority to JP2006532522A priority Critical patent/JP2007500212A/en
Priority to AU2004255153A priority patent/AU2004255153B2/en
Priority to EP04775923A priority patent/EP1622684A4/en
Priority to MXPA05011741A priority patent/MXPA05011741A/en
Priority to CA2524394A priority patent/CA2524394C/en
Publication of WO2005004988A2 publication Critical patent/WO2005004988A2/en
Publication of WO2005004988A3 publication Critical patent/WO2005004988A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
PCT/US2004/013455 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof WO2005004988A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006532522A JP2007500212A (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and their targets
AU2004255153A AU2004255153B2 (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof
EP04775923A EP1622684A4 (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof
MXPA05011741A MXPA05011741A (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof.
CA2524394A CA2524394C (en) 2003-05-01 2004-04-30 Novel benzodiazepine compounds, compositions and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10/427,212 2003-05-01
US10/427,211 US7572788B2 (en) 1999-04-30 2003-05-01 Compositions and methods relating to novel compounds and targets thereof
US10/427,212 US7144880B2 (en) 1999-04-30 2003-05-01 Compositions relating to novel compounds and targets thereof
US10/427,211 2003-05-01
US10/634,114 US20040176358A1 (en) 1999-04-30 2003-08-04 Compositions and methods relating to novel compounds and targets thereof
US10/634,114 2003-08-04
US10/795,535 US7276348B2 (en) 1999-04-30 2004-03-08 Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US10/795,535 2004-03-08

Publications (2)

Publication Number Publication Date
WO2005004988A2 WO2005004988A2 (en) 2005-01-20
WO2005004988A3 true WO2005004988A3 (en) 2006-02-23

Family

ID=34069318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013455 WO2005004988A2 (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof

Country Status (6)

Country Link
EP (1) EP1622684A4 (en)
JP (1) JP2007500212A (en)
AU (1) AU2004255153B2 (en)
CA (1) CA2524394C (en)
MX (1) MXPA05011741A (en)
WO (1) WO2005004988A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683046B2 (en) 1999-04-30 2010-03-23 The Regents Of The University Of Michigan Benzodiazepine compositions for treating epidermal hyperplasia and related disorders
US7851465B2 (en) 2007-03-09 2010-12-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8415343B2 (en) 1999-04-30 2013-04-09 The Regents Of The University Of Michigan Compositions and methods for inhibiting the proliferation of cells
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
DE60007960T2 (en) 1999-04-30 2004-10-21 Univ Michigan Ann Arbor Therapeutic applications of pro-apoptotic benzodiazepines
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7638624B2 (en) 2005-01-03 2009-12-29 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and derivatives
JP2008545757A (en) * 2005-06-01 2008-12-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Unsolvated benzodiazepine compositions and methods
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066106A2 (en) * 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
AU2002332560B2 (en) * 2001-08-15 2006-01-19 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
WO2000066106A2 (en) * 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1622684A4 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683046B2 (en) 1999-04-30 2010-03-23 The Regents Of The University Of Michigan Benzodiazepine compositions for treating epidermal hyperplasia and related disorders
US8168626B2 (en) 1999-04-30 2012-05-01 The Regents Of The University Of Michigan Benzodiazepine compositions for treating epidermal hyperplasia and related disorders
US8415343B2 (en) 1999-04-30 2013-04-09 The Regents Of The University Of Michigan Compositions and methods for inhibiting the proliferation of cells
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7851465B2 (en) 2007-03-09 2010-12-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8242109B2 (en) 2007-03-09 2012-08-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8461153B2 (en) 2007-11-06 2013-06-11 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8759340B2 (en) 2007-11-06 2014-06-24 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
EP1622684A2 (en) 2006-02-08
WO2005004988A2 (en) 2005-01-20
MXPA05011741A (en) 2006-05-12
CA2524394A1 (en) 2005-01-20
EP1622684A4 (en) 2007-07-25
AU2004255153B2 (en) 2007-11-22
JP2007500212A (en) 2007-01-11
CA2524394C (en) 2011-07-12
AU2004255153A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
WO2006029245A3 (en) Compositions and methods relating to novel compounds and targets thereof
WO2006014526A3 (en) Compositions and methods relating to novel compounds and targets thereof
WO2005004988A3 (en) Compositions and methods relating to novel compounds and targets thereof
WO2007053725A3 (en) Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
WO2003015703A3 (en) Compositions and methods relating to novel benzodiazepine compounds and targets thereof
WO2006073448A3 (en) Methods and compositions for treating diseases and conditions associated with mitochondrial function
MX2009009645A (en) Compositions and methods relating to novel compounds and targets thereof.
WO2008116156A3 (en) Methods and compositions for treating diseases and conditions associated with mitochondrial function
WO2007050587A3 (en) Therapeutic compositions and methods
WO2004112719A3 (en) Chemical compounds
EP1507529B8 (en) Combination comprising valsartan, amlodipine and hydrochlorothiazide
WO2003087094A3 (en) Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
NO20055863L (en) W-carboxyaryl-substituted diphenylurea compounds as raf kinase inhibitors
WO2008012532A3 (en) : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
WO2004017920A3 (en) Novel biphenyl and biphenyl-like cannabinoids
ZA200409862B (en) Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
WO2005121097A3 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2003095455A3 (en) Substituted pyrazolopyrimidines
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
GEP20084539B (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2524394

Country of ref document: CA

Ref document number: PA/a/2005/011741

Country of ref document: MX

Ref document number: 2006532522

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004255153

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2004775923

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004775923

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004255153

Country of ref document: AU

Date of ref document: 20040430

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004255153

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004775923

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004255153

Country of ref document: AU

Date of ref document: 20040430

Kind code of ref document: B